Literature DB >> 18836802

Institutional indications for islet transplantation after total pancreatectomy.

Naoaki Sakata1, Shinichi Egawa, Fuyuhiko Motoi, Yukio Mikami, Masaharu Ishida, Takeshi Aoki, Shigeru Ottomo, Shoji Fukuyama, Toshiki Rikiyama, Yu Katayose, Masafumi Goto, Michiaki Unno.   

Abstract

BACKGROUND/
PURPOSE: This study was designed to establish institutional indications for pancreatic islet transplantation by examining patients with total pancreatectomy as candidates for islet allotransplantation.
METHODS: In 12 patients who underwent total pancreatectomy, we compared pre-and postoperative plasma glucose level, body mass index, HbA1c, and daily insulin use; we examined candidacy for islet allotransplantation based on the guidelines of Japan's islet transplantation registry.
RESULTS: Eight of the 12 patients with total pancreatectomy were operated for intraductal papillary mucinous neoplasm. At our institution, the 5-year survival of patients with intraductal papillary mucinous neoplasm was far better (76.3%) than that of patients with pancreatic cancer. Postoperatively, plasma glucose level, HbA1c, and daily insulin use were increased in all patients with total pancreatectomy. Of the 12 patients treated with total pancreatectomy, 4 (intraductal papillary mucinous neoplasm, n = 2; islet cell tumor, n = 1; and acute pancreatitis due to arteriovenous malformation, n = 1) showed deteriorated diabetic control and therefore were considered to be candidates for islet allotransplantation according to the guidelines.
CONCLUSIONS: Islet allotransplantation could be indicated for patients with favorable postoperative survival who have had a total pancreatectomy for either benign or neoplastic disease.

Entities:  

Mesh:

Year:  2008        PMID: 18836802     DOI: 10.1007/s00534-007-1309-3

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  7 in total

1.  Pancreaticoduodenectomy with resection of the splenic artery and splenectomy for pancreatic double cancers after total gastrectomy. Preservation of the pancreatic function via the blood supply from the posterior epiploic artery: report of a case.

Authors:  Shugo Mizuno; Shuji Isaji; Ichiro Ohsawa; Masashi Kishiwada; Takashi Hamada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

2.  Encapsulated islets transplantation: Past, present and future.

Authors:  Naoaki Sakata; Shoichiro Sumi; Gumpei Yoshimatsu; Masafumi Goto; Shinichi Egawa; Michiaki Unno
Journal:  World J Gastrointest Pathophysiol       Date:  2012-02-15

3.  Nonfunctioning pancreatic endocrine tumor with extension into the main pancreatic duct: report of a case.

Authors:  Naoki Yazawa; Toshihide Imaizumi; Ken-ichi Okada; Masahiro Matsuyama; Shoichi Dowaki; Kosuke Tobita; Yasuo Ohtani; Kyoji Ogoshi; Kenichi Hirabayashi; Hiroyasu Makuuchi
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

Review 4.  Diabetes after pancreatic surgery: novel issues.

Authors:  Marina Scavini; Erica Dugnani; Valentina Pasquale; Daniela Liberati; Francesca Aleotti; Gaetano Di Terlizzi; Giovanna Petrella; Gianpaolo Balzano; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

Review 5.  Autologous islet transplantation in patients requiring pancreatectomy for neoplasm.

Authors:  Gianpaolo Balzano; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

6.  Perioperative outcomes of pancreaticoduodenectomy compared to total pancreatectomy for neoplasia.

Authors:  Neil H Bhayani; Jennifer L Miller; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani
Journal:  J Gastrointest Surg       Date:  2013-10-29       Impact factor: 3.452

Review 7.  Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes.

Authors:  Rosita Primavera; Bhavesh D Kevadiya; Ganesh Swaminathan; Rudilyn Joyce Wilson; Angelo De Pascale; Paolo Decuzzi; Avnesh S Thakor
Journal:  Nanomaterials (Basel)       Date:  2020-04-20       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.